Table 6 Lymphocyte subpopulations: recurrent patients vs. disease-free patients

Gran %CD45

2.22 ± 4.38

6.65 ± 7.52

0.147

10.66 ± 13.45

8.28 ± 8.24

0.682

T %MNC

57.32 ± 13.27

57.83 ± 11.21

0.921

68.67 ± 19.01

71.23 ± 11.52

0.754

CD4%T

57.45 ± 10.67

48.50 ± 18.24

0.071

48.07 ± 14.41

33.12 ± 13.59

0.018^#

CD8%T

30.38 ± 8.59

36.41 ± 17.03

0.151

42.87 ± 13.46

57.92 ± 10.76

0.015^#

CD4:CD8

2.14 ± 0.97

1.65 ± 0.85

0.196

1.32 ± 0.75

0.62 ± 0.34

0.032^#

rdT %T

7.21 ± 4.54

9.30

0.657

2.73 ± 2.00

2.22 ± 1.23

0.571

B % MNC

6.13 ± 3.31

5.61 ± 1.93

0.693

5.36 ± 3.62

3.65 ± 1.78

0.270

pDC % MNC

0.24 ± 0.12

0.26 ± 0.16

0.696

0.69 ± 0.84

0.47 ± 0.41

0.541

CD11c + % pDC

8.05 ± 5.19

4.63 ± 2.41

0.208

5.92 ± 4.90

5.27 ± 4.20

0.769

Baso % MNC

0.89 ± 0.63

1.36 ± 0.91

0.091

0.10 ± 0.17

0.03 ± 0.08

0.390

BDCA1+ mDC % MNC

0.37 ± 0.19

0.43 ± 0.10

0.595

0.12 ± 0.15

0.07 ± 0.05

0.382

BDCA3+ mDC % MNC

0.02 ± 0.04

0

0.022^#

0.02 ± 0.07

.0000

0.441

Mono % MNC

14.97 ± 9.08

18.13 ± 10.17

0.391

7.89 ± 7.83

10.98 ± 10.67

0.413

CD14+ Mo % MNC

14.35 ± 7.29

16.63 ± 4.44

0.550

1.90 ± 2.03

3.37 ± 3.23

0.175

CD16+ Mo % MNC

2.91 ± 1.89

4.20 ± 3.91

0.560

5.14 ± 5.30

7.62 ± 7.46

0.357

CD16+ %Mono

17.40 ± 7.24

18.80 ± 12.82

0.745

72.16 ± 13.58

71.30 ± 12.18

0.889

NK %MNC

16.85 ± 9.95

12.37 ± 4.01

0.251

6.12 ± 13.48

3.98 ± 6.32

0.709

CD56hi NK % MNC

0.33 ± 0.15

0.30 ± 0.12

0.693

4.50 ± 12.69

3.40 ± 5.76

0.839

CD56lo NK % MNC

17.68 ± 10.17

14.35 ± 3.59

0.527

1.37 ± 2.10

0.55 ± 0.60

0.357

CD56hi %NK

2.61 ± 2.19

2.05 ± 0.58

0.616

64.10 ± 24.34

74.82 ± 21.91

0.337

MDSC % CD33hi

1.53 ± 2.84

4.08 ± 5.80

0.155

2.67 ± 4.16

1.42 ± 1.30

0.479

DR- %14 + APC

0.58 ± 1.65

0.08 ± 0.15

0.554

16.21 ± 17.23

24.48 ± 22.78

0.335

DR- %16 + APC

1.00 ± 1.68

0.05 ± 0.06

0.272

1.29 ± 2.18

2.75 ± 4.98

0.284